X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (40) 40
humans (35) 35
immunotherapy (35) 35
nivolumab (33) 33
oncology (22) 22
male (20) 20
cancer (18) 18
aged (17) 17
ipilimumab (17) 17
melanoma (17) 17
apoptosis (15) 15
female (15) 15
middle aged (15) 15
anti-programmed cell death-1 (14) 14
dermatology (14) 14
programmed cell death 1 receptor - antagonists & inhibitors (14) 14
antibodies, monoclonal - therapeutic use (13) 13
care and treatment (13) 13
case report (13) 13
medicine, research & experimental (13) 13
antibodies, monoclonal - adverse effects (12) 12
antineoplastic agents - therapeutic use (12) 12
pembrolizumab (12) 12
therapy (12) 12
antineoplastic agents - adverse effects (11) 11
safety (11) 11
adult (10) 10
aged, 80 and over (10) 10
chemotherapy (10) 10
metastatic melanoma (10) 10
anti-programmed death-1 (9) 9
metastasis (9) 9
treatment outcome (9) 9
advanced melanoma (8) 8
melanoma - drug therapy (8) 8
patients (8) 8
antibodies, monoclonal, humanized - therapeutic use (7) 7
antigens (7) 7
cancer therapies (7) 7
development and progression (7) 7
expression (7) 7
lung cancer (7) 7
skin neoplasms - drug therapy (7) 7
young adult (7) 7
antibodies, monoclonal, humanized - adverse effects (6) 6
antibody (6) 6
antineoplastic agents, immunological - adverse effects (6) 6
cell death (6) 6
drug therapy (6) 6
health aspects (6) 6
immunotherapy - methods (6) 6
monoclonal antibodies (6) 6
open-label (6) 6
programmed cell death 1 receptor - immunology (6) 6
tumors (6) 6
anti-pd-1 (5) 5
anti-programmed cell death-1 antibody (5) 5
anti-programmed death-1 antibody (5) 5
antibodies (5) 5
antineoplastic agents, immunological - therapeutic use (5) 5
biochemistry (5) 5
immune checkpoint (5) 5
lung neoplasms - drug therapy (5) 5
medicine, general & internal (5) 5
neoplasms. tumors. oncology. including cancer and carcinogens (5) 5
pd-1 blockade (5) 5
research (5) 5
survival (5) 5
t cells (5) 5
usage (5) 5
adverse events (4) 4
animals (4) 4
articles (4) 4
biotechnology & applied microbiology (4) 4
carcinoma, renal cell - drug therapy (4) 4
cell lung-cancer (4) 4
complications and side effects (4) 4
cutaneous adverse event (4) 4
diabetes (4) 4
lymphocytes (4) 4
management (4) 4
mutation (4) 4
neoplasm metastasis (4) 4
non-small cell lung cancer (4) 4
pd-1 (4) 4
prognosis (4) 4
programmed cell death 1 receptor - metabolism (4) 4
respiratory system (4) 4
retrospective studies (4) 4
risk factors (4) 4
skin neoplasms - pathology (4) 4
viral antibodies (4) 4
adolescent (3) 3
analysis (3) 3
anti-cytotoxic t-lymphocyte-associated protein 4 (3) 3
anti-pd-l1 antibody (3) 3
anti-programmed cell death 1 (3) 3
anti-programmed cell death-1 therapy (3) 3
anti-programmed-death-1 (3) 3
antibodies, monoclonal - pharmacology (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 12/2018, Volume 105, pp. 88 - 102
Journal Article
JOURNAL OF DIABETES INVESTIGATION, ISSN 2040-1116, 11/2016, Volume 7, Issue 6, pp. 915 - 918
Anti-programmed cell death-1 (PD-1) antibodies are regarded as a risk factor for insulin-dependent diabetes mellitus as a side-effect. While a small number of... 
Anti-programmed cell death-1 antibodies | Fulminant type1 diabetes | Nivolumab | ENDOCRINOLOGY & METABOLISM
Journal Article
JOURNAL OF THORACIC ONCOLOGY, ISSN 1556-0864, 12/2019, Volume 14, Issue 12, pp. 2071 - 2083
Introduction: Programmed cell death-1 (PD-1) inhibitors effectively treat NSCLC and prolong survival. Robust biomarkers for predicting clinical benefits of... 
Biomarker | NSCLC | LUNG ADENOCARCINOMA PATIENTS | INDUCTION | CANCER | Anti-programmed death 1 therapy | BIOMARKERS | ONCOLOGY | GAGED2A | IMMUNOTHERAPY | RESPIRATORY SYSTEM | Serum antibody | Cancer-testis antigen | PD-1 | EXPRESSION | IMMUNE-CHECKPOINT BLOCKADE | T-CELLS
Journal Article
Journal of Diabetes Investigation, ISSN 2040-1116, 11/2016, Volume 7, Issue 6, pp. 915 - 918
Journal Article
Journal Article
Journal Article
Melanoma research, ISSN 0960-8931, 04/2018, Volume 28, Issue 2, pp. 111 - 119
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 76, Issue 5, pp. 863 - 870
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 68, pp. 113287 - 113293
The US FDA granted accelerated approval to pembrolizumab for microsatellite instability-high and mismatch repair deficient cancers. The response of programmed... 
Anti-programmed death-1 antibody | Nasopharyngeal carcinoma | Microsatellite instability-high | Mismatch repair proficiency | CELL BIOLOGY | CELL LUNG-CANCER | IRRADIATION | ANTI-PD-L1 ANTIBODY | PEMBROLIZUMAB | THERAPY | ANTITUMOR IMMUNE-RESPONSES | IMMUNOTHERAPY | CLINICAL-APPLICATIONS | PD-L1 | EXPRESSION
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1803 - 1813
Journal Article